Alnylam Pharmaceuticals, Inc. (ALNY) stock
ALNYNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 10/3047% below fair value
$156.50−3.23 (-2.02%)
Close on Nov 17, 2026Market cap $20.96BP/E 8.1Yield –
Alnylam Pharmaceuticals r&d expenses
Research and development expenses are spending on new products and technology.
Alnylam Pharmaceuticals's R&D Expenses for the twelve months ending Sep 30, 2026 was $1.56B, up 24.9% year over year. For fiscal 2025 it was $1.32B, up 17.2% from the year before. Over ten years it grew 16.9% a year on average. The highest annual figure on record is $1.32B in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.32B | +17.2% |
| FY2024 | Dec 31, 2024 | $1.13B | +12.1% |
| FY2023 | Dec 31, 2023 | $1.00B | +13.7% |
| FY2022 | Dec 31, 2022 | $883.02M | +11.5% |
| FY2021 | Dec 31, 2021 | $792.16M | +21.0% |
| FY2020 | Dec 31, 2020 | $654.82M | -0.0% |
| FY2019 | Dec 31, 2019 | $655.11M | +29.6% |
| FY2018 | Dec 31, 2018 | $505.42M | +29.4% |
| FY2017 | Dec 31, 2017 | $390.64M | +2.2% |
| FY2016 | Dec 31, 2016 | $382.39M | +38.3% |
| FY2015 | Dec 31, 2015 | $276.50M | +45.3% |
| FY2014 | Dec 31, 2014 | $190.25M | +68.4% |
| FY2013 | Dec 31, 2013 | $112.96M | +30.5% |
| FY2012 | Dec 31, 2012 | $86.57M | -12.8% |
| FY2011 | Dec 31, 2011 | $99.30M | -6.7% |
| FY2010 | Dec 31, 2010 | $106.38M | -2.2% |
| FY2009 | Dec 31, 2009 | $108.73M | +12.2% |
| FY2008 | Dec 31, 2008 | $96.88M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $408.54M | +13.9% |
| Q2 FY2026 | Jun 30, 2026 | $413.13M | +27.7% |
| Q1 FY2026 | Mar 31, 2026 | $364.87M | +37.6% |
| Q4 FY2025 | Dec 31, 2025 | $372.22M | +24.0% |
| Q3 FY2025 | Sep 30, 2025 | $358.81M | +32.4% |
| Q2 FY2025 | Jun 30, 2025 | $323.62M | +10.0% |
| Q1 FY2025 | Mar 31, 2025 | $265.12M | +1.6% |
| Q4 FY2024 | Dec 31, 2024 | $300.17M | +10.3% |
| Q3 FY2024 | Sep 30, 2024 | $270.93M | +7.0% |
| Q2 FY2024 | Jun 30, 2024 | $294.14M | +18.4% |
| Q1 FY2024 | Mar 31, 2024 | $261.00M | +13.2% |
| Q4 FY2023 | Dec 31, 2023 | $272.14M | +3.9% |
| Q3 FY2023 | Sep 30, 2023 | $253.18M | +3.2% |
| Q2 FY2023 | Jun 30, 2023 | $248.53M | +20.8% |
| Q1 FY2023 | Mar 31, 2023 | $230.57M | +35.7% |
| Q4 FY2022 | Dec 31, 2022 | $262.04M | +14.4% |
| Q3 FY2022 | Sep 30, 2022 | $245.37M | +26.1% |
| Q2 FY2022 | Jun 30, 2022 | $205.71M | +12.6% |
| Q1 FY2022 | Mar 31, 2022 | $169.89M | -8.6% |
| Q4 FY2021 | Dec 31, 2021 | $229.05M | +36.0% |
| Q3 FY2021 | Sep 30, 2021 | $194.57M | +20.3% |
| Q2 FY2021 | Jun 30, 2021 | $182.64M | +17.8% |
| Q1 FY2021 | Mar 31, 2021 | $185.90M | +9.6% |
| Q4 FY2020 | Dec 31, 2020 | $168.47M | -16.3% |
| Q3 FY2020 | Sep 30, 2020 | $161.78M | +0.6% |
| Q2 FY2020 | Jun 30, 2020 | $155.00M | -5.4% |
| Q1 FY2020 | Mar 31, 2020 | $169.57M | +31.3% |
| Q4 FY2019 | Dec 31, 2019 | $201.30M | +53.6% |
| Q3 FY2019 | Sep 30, 2019 | $160.80M | +14.9% |
| Q2 FY2019 | Jun 30, 2019 | $163.89M | +19.1% |
| Q1 FY2019 | Mar 31, 2019 | $129.13M | +33.3% |
| Q4 FY2018 | Dec 31, 2018 | $131.04M | +11.3% |
| Q3 FY2018 | Sep 30, 2018 | $139.95M | +46.9% |
| Q2 FY2018 | Jun 30, 2018 | $137.58M | +51.8% |
| Q1 FY2018 | Mar 31, 2018 | $96.86M | +11.4% |
| Q4 FY2017 | Dec 31, 2017 | $117.77M | +12.2% |
| Q3 FY2017 | Sep 30, 2017 | $95.25M | – |
| Q2 FY2017 | Jun 30, 2017 | $90.63M | – |
| Q1 FY2017 | Mar 31, 2017 | $86.98M | – |
| Q4 FY2016 | Dec 31, 2016 | $105.01M | – |
See a number that looks wrong?